Skip to main content
MedPathMedPath Home
Clinical Trials/2023-509969-20-00
2023-509969-20-00
Completed
Phase 1

This is clinical study to test, for the first time in people, the safety (any good or bad effects), how long the drug can stay in the body and if it can control the disease of people diagnosed with advanced cancer that has not responded to treatment, has returned after it has been treated, or cannot be treated by surgery, drugs, or any other known treatments.

Celgene Corp.4 sites in 2 countries127 target enrollmentStarted: February 21, 2024Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 1
Status
Completed
Enrollment
127
Locations
4
OverviewEligibility CriteriaInvestigatorsSitesRecords & IdentifiersSimilar Trials

Overview

Brief Summary

No summary available.

Eligibility Criteria

Ages
18 years to 65+ years (18-64 Years, 65+ Years)
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Investigators

Sponsor Class
Pharmaceutical company
Responsible Party
Principal Investigator
Principal Investigator

GSM-CT

Scientific

Celgene Corp.

Study Sites (4)

Loading locations...

Similar Trials

Recruiting
Phase 1
clinical trial to determine the feasibility and safety of the mesenchymal stem cells use in women over 50 years of age with urinary incontinencee
2024-514833-39-00Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz60
Completed
Phase 1
A clinical trial in healthy people to look at how the body processes RO7268489 over time and when taken before or after a meal
2023-503528-25-00F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG36
Not yet recruiting
Not Applicable
PROSPECTIVE RANDOMISED CLINICAL TRIAL TO EVALUATE THE EARLY RECURRENCE RATE IN NON-MUSCLE INVASIVE BLADDER CANCER BETWEEN THE USE OF CHEMOHYPERTHERMIA (QH) WITH MITOMYCIN-C PRIOR TO TRANSURETHRAL BLADDER RESECTION IN A MAJOR OUTPATIENT SURGERY PROGRAMME AND TREATMENT WITH MITOMYCIN-C IN NORMOTHERMIA POST-RESECTION.
2024-519890-21-00University Hospital Of Canary Islands152
Recruiting
Phase 1
First in human clinical trial to evaluate the safety, tolerability and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer
2022-503084-15-00Deutsches Krebsforschungszentrum (DKFZ)77
Active, not recruiting
Phase 1
First-in-human study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of VTX-PID in healthy male volunteers
2023-503892-83-00Vivet Therapeutics35